Cargando…

2902. Dalbavancin Use in Bone and Joint Infections

BACKGROUND: Dalbavancin (DAL) is currently FDA-approved to treat acute bacterial skin and soft tissue infections. Use of DAL for off-label indications have been reported in difficult-to-treat infections, including osteomyelitis and prosthetic joint infections. Once weekly DAL dosing is an attractive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanikommu, Srivani, Alderson, Liam P, Bailey, Brett, Stambough, Jeffrey, Stronach, Benjamin, Mears, Simon, Dare, Ryan K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678224/ http://dx.doi.org/10.1093/ofid/ofad500.173

Ejemplares similares

2902. Pertussis Antibody Levels in Preterm Infants After Maternal Tdap Immunization During Pregnancy
por: Healy, C Mary, et al.
Publicado: (2019)

Development of VRE meningitis due to haematogenous spread while on high-dose daptomycin therapy
por: Sanikommu, Srivani, et al.
Publicado: (2023)

Dalbavancin in Bone and Joint Infections: A Systematic Review
por: Lovatti, Sofia, et al.
Publicado: (2023)

Articulating Hip Spacers with a Constrained Acetabular Liner: Effect of Acetabular Bone Loss and Cementation Quality
por: Glenn, Grayson T., et al.
Publicado: (2023)

Piezo1 opposes age‐associated cortical bone loss
por: Li, Xuehua, et al.
Publicado: (2023)

234. Dalbavancin versus Outpatient Parenteral Antimicrobial Therapy with Vancomycin for Treatment of Bone and Joint Infections in a Veteran Population
por: Gibbons, Emily A, et al.
Publicado: (2021)

A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections
por: Dimopoulou, Dimitra, et al.
Publicado: (2023)

Catastrophic Trunnion Failure in an Anatomic Titanium Alloy Stem
por: Pruitt, Benjamin P., et al.
Publicado: (2022)

Leg Length Discrepancy After Hip Fracture Repair is Associated With Reduced Gait Speed
por: Pearce, Alexa N., et al.
Publicado: (2023)

Total Knee Periprosthetic Joint Infection in the Setting of Hematologic Malignancy: Considerations for Management
por: Bloom, G. Barnes, et al.
Publicado: (2020)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

238. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2021)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

2765. Dalbavancin for challenging left ventricular assist device driveline infections
por: Doligalski, Christina, et al.
Publicado: (2023)

Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States (US) Medical Centers (2011–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
por: Brescini, Lucia, et al.
Publicado: (2021)

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
por: Buzón-Martín, Luis, et al.
Publicado: (2021)

Impact of an Antimicrobial Stewardship and Emergency Department Initiated Dalbavancin Guideline for Patients with Acute Bacterial Skin and Soft-Tissue Infections
por: Burgess, Donna R, et al.
Publicado: (2017)

1286. Evaluating Dalbavancin Suppression Therapy in Patients at High Risk for Recurrent Infections
por: Shaw, Michael, et al.
Publicado: (2023)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

Corneal Abrasions in Total Joint Arthroplasty
por: Young, Megan E., et al.
Publicado: (2021)

1247. Dalbavancin in Osteomyelitis and Joint Infections: An Analysis From an Observational, Multicenter, Retrospective Cohort Study of the Real-World Use in Adult Patients
por: Diaz, Julia Garcia, et al.
Publicado: (2020)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

438. Dalbavancin Clinical Experience at an NCI Designated Cancer Center
por: McDaneld, Patrick, et al.
Publicado: (2019)

225. Dalbavancin Usage in Patients Who Inject Drugs (PWID)
por: Patel, Kaya, et al.
Publicado: (2023)

Management of Periprosthetic Joint Infection and Extensor Mechanism Disruption With Modular Knee Fusion: Clinical and Biomechanical Outcomes
por: Mayes, Wesley H., et al.
Publicado: (2021)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin
por: Söderquist, Bo, et al.
Publicado: (2023)

Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
por: Lange, Anna, et al.
Publicado: (2023)

1828. Dalbavancin Utilization and Associated Clinical Outcomes: A Case-Series
por: Greckel, Meagan N, et al.
Publicado: (2022)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

398 Pharmacokinetics of dalbavancin (DAL) in bone and associated tissues in patients undergoing orthopedic surgical procedures
por: Baldassarre, James, et al.
Publicado: (2014)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m09valq5fb6rnjl5keomj7lavr